Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs

Abstract Background Extracorporeal life support (ECLS) has become an integral part of modern intensive therapy. The choice of support mode depends largely on the indication. Patients with respiratory failure are predominantly treated with a venovenous (VV) approach. We hypothesized that mortality in...

Full description

Bibliographic Details
Main Authors: Benjamin Friedrichson, Haitham Mutlak, Kai Zacharowski, Florian Piekarski
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Critical Care
Subjects:
Online Access:https://doi.org/10.1186/s13054-021-03463-2
_version_ 1828926059676958720
author Benjamin Friedrichson
Haitham Mutlak
Kai Zacharowski
Florian Piekarski
author_facet Benjamin Friedrichson
Haitham Mutlak
Kai Zacharowski
Florian Piekarski
author_sort Benjamin Friedrichson
collection DOAJ
description Abstract Background Extracorporeal life support (ECLS) has become an integral part of modern intensive therapy. The choice of support mode depends largely on the indication. Patients with respiratory failure are predominantly treated with a venovenous (VV) approach. We hypothesized that mortality in Germany in ECLS therapy did not differ from previously reported literature Methods Inpatient data from Germany from 2007 to 2018 provided by the Federal Statistical Office of Germany were analysed. The international statistical classification of diseases and related health problems codes (ICD) and process keys (OPS) for extracorporeal membrane oxygenation (ECMO) types, acute respiratory distress syndrome (ARDS) and hospital mortality were used. Results In total, 45,647 hospitalized patients treated with ECLS were analysed. In Germany, 231 hospitals provided ECLS therapy, with a median of 4 VV-ECMO and 9 VA-ECMO in 2018. Overall hospital mortality remained higher than predicted in comparison to the values reported in the literature. The number of VV-ECMO cases increased by 236% from 825 in 2007 to 2768 in 2018. ARDS was the main indication for VV-ECMO in only 33% of the patients in the past, but that proportion increased to 60% in 2018. VA-ECMO support is of minor importance in the treatment of ARDS in Germany. The age distribution of patients undergoing ECLS has shifted towards an older population. In 2018, the hospital mortality decreased in VV-ECMO patients and VV-ECMO patients with ARDS to 53.9% (n = 1493) and 54.4% (n = 926), respectively. Conclusions ARDS is a severe disease with a high mortality rate despite ECLS therapy. Although endpoints and timing of the evaluations differed from those of the CESAR and EOLIA studies and the Extracorporeal Life Support Organization (ELSO) Registry, the reported mortality in these studies was lower than in the present analysis. Further prospective analyses are necessary to evaluate outcomes in ECMO therapy at the centre volume level.
first_indexed 2024-12-13T23:26:01Z
format Article
id doaj.art-44333087fe6e4265b231faa1017e7c49
institution Directory Open Access Journal
issn 1364-8535
language English
last_indexed 2024-12-13T23:26:01Z
publishDate 2021-01-01
publisher BMC
record_format Article
series Critical Care
spelling doaj.art-44333087fe6e4265b231faa1017e7c492022-12-21T23:27:33ZengBMCCritical Care1364-85352021-01-0125111010.1186/s13054-021-03463-2Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runsBenjamin Friedrichson0Haitham Mutlak1Kai Zacharowski2Florian Piekarski3Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe UniversityDepartment of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe UniversityDepartment of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe UniversityDepartment of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe UniversityAbstract Background Extracorporeal life support (ECLS) has become an integral part of modern intensive therapy. The choice of support mode depends largely on the indication. Patients with respiratory failure are predominantly treated with a venovenous (VV) approach. We hypothesized that mortality in Germany in ECLS therapy did not differ from previously reported literature Methods Inpatient data from Germany from 2007 to 2018 provided by the Federal Statistical Office of Germany were analysed. The international statistical classification of diseases and related health problems codes (ICD) and process keys (OPS) for extracorporeal membrane oxygenation (ECMO) types, acute respiratory distress syndrome (ARDS) and hospital mortality were used. Results In total, 45,647 hospitalized patients treated with ECLS were analysed. In Germany, 231 hospitals provided ECLS therapy, with a median of 4 VV-ECMO and 9 VA-ECMO in 2018. Overall hospital mortality remained higher than predicted in comparison to the values reported in the literature. The number of VV-ECMO cases increased by 236% from 825 in 2007 to 2768 in 2018. ARDS was the main indication for VV-ECMO in only 33% of the patients in the past, but that proportion increased to 60% in 2018. VA-ECMO support is of minor importance in the treatment of ARDS in Germany. The age distribution of patients undergoing ECLS has shifted towards an older population. In 2018, the hospital mortality decreased in VV-ECMO patients and VV-ECMO patients with ARDS to 53.9% (n = 1493) and 54.4% (n = 926), respectively. Conclusions ARDS is a severe disease with a high mortality rate despite ECLS therapy. Although endpoints and timing of the evaluations differed from those of the CESAR and EOLIA studies and the Extracorporeal Life Support Organization (ELSO) Registry, the reported mortality in these studies was lower than in the present analysis. Further prospective analyses are necessary to evaluate outcomes in ECMO therapy at the centre volume level.https://doi.org/10.1186/s13054-021-03463-2ARDSExtracorporeal life supportECMOOPSMortality
spellingShingle Benjamin Friedrichson
Haitham Mutlak
Kai Zacharowski
Florian Piekarski
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
Critical Care
ARDS
Extracorporeal life support
ECMO
OPS
Mortality
title Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
title_full Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
title_fullStr Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
title_full_unstemmed Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
title_short Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
title_sort insight into ecmo mortality and ards a nationwide analysis of 45 647 ecmo runs
topic ARDS
Extracorporeal life support
ECMO
OPS
Mortality
url https://doi.org/10.1186/s13054-021-03463-2
work_keys_str_mv AT benjaminfriedrichson insightintoecmomortalityandardsanationwideanalysisof45647ecmoruns
AT haithammutlak insightintoecmomortalityandardsanationwideanalysisof45647ecmoruns
AT kaizacharowski insightintoecmomortalityandardsanationwideanalysisof45647ecmoruns
AT florianpiekarski insightintoecmomortalityandardsanationwideanalysisof45647ecmoruns